Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019;16(7):411–28.

Article  PubMed  Google Scholar 

Dufour J-F, Scherer R, Balp M-M, McKenna SJ, Janssens N, Lopez P, et al. The global epidemiology of nonalcoholic steatohepatitis (NASH) and associated risk factors–A targeted literature review. Endocr Metab Sci. 2021;3:100089.

Article  CAS  Google Scholar 

Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274–85.

Article  CAS  PubMed  Google Scholar 

Hamid O, Eltelbany A, Mohammed A, Alsabbagh Alchirazi K, Trakroo S, Asaad I. The epidemiology of non-alcoholic steatohepatitis (NASH) in the United States between 2010–2020: a population-based study. Ann Hepatol. 2022;27(5):100727.

Article  PubMed  Google Scholar 

Witkowski M, Moreno SI, Fernandes J, Johansen P, Augusto M, Nair S. The economic burden of non-alcoholic steatohepatitis: a systematic review. Pharmacoeconomics. 2022;40(8):751–76.

Article  PubMed  PubMed Central  Google Scholar 

Dufour J-F, Anstee QM, Bugianesi E, Harrison S, Loomba R, Paradis V, et al. Current therapies and new developments in NASH. Gut. 2022;71(10):2123–34.

Article  CAS  PubMed  Google Scholar 

Younossi Z, Aggarwal P, Shrestha I, Fernandes J, Johansen P, Augusto M, et al. The burden of non-alcoholic steatohepatitis: a systematic review of health-related quality of life and patient-reported outcomes. JHEP Rep. 2022;4(9):100525.

Article  PubMed  PubMed Central  Google Scholar 

Younossi ZM, Stepanova M, Younossi I, Racila A. Validation of chronic liver disease questionnaire for nonalcoholic steatohepatitis in patients with biopsy-proven nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2019;17(10):2093-2100.e2093.

Article  PubMed  Google Scholar 

Longworth L, Yang Y, Young T, Mulhern B, Hernández Alava M, Mukuria C, et al. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. Health Technol Assess. 2014;18(9):1–224.

Article  PubMed  PubMed Central  Google Scholar 

EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208.

Article  Google Scholar 

Position statement on use of the EQ-5D-5L value set for England (updated October 2019). Available from: https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/technology-appraisal-guidance/eq-5d-5l.

ICER's reference case for economic evaluations: Principles and rationale. Available from: https://icer.org/wp-content/uploads/2020/10/ICER_Reference_Case_013120.pdf.

Longworth L, Rowen D. NICE decision support unit technical support documents. In: NICE DSU technical support document 10: the use of mapping methods to estimate health state utility values. London: National Institute for Health and Care Excellence (NICE); 2011.

Google Scholar 

Brazier JE, Yang Y, Tsuchiya A, Rowen DL. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ. 2010;11(2):215–25.

Article  PubMed  Google Scholar 

Wailoo AJ, Hernandez-Alava M, Manca A, Mejia A, Ray J, Crawford B, et al. Mapping to estimate health-state utility from non-preference-based outcome measures: an ISPOR good practices for outcomes research task force report. Value Health. 2017;20(1):18–27.

Article  PubMed  Google Scholar 

Younossi ZM, Stepanova M, Nader F, Loomba R, Anstee QM, Ratziu V, et al. Obeticholic acid impact on quality of life in patients with nonalcoholic steatohepatitis: REGENERATE 18-month interim analysis. Clin Gastroenterol Hepatol. 2022;20(9):2050-2058.e2012.

Article  CAS  PubMed  Google Scholar 

Younossi ZM, Stepanova M, Noureddin M, Kowdley KV, Strasser SI, Kohli A, et al. Improvements of fibrosis and disease activity are associated with improvement of patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis. Hepatol Commun. 2021;5(7):1201–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: disease-specific programmes - a means to understand. Curr Med Res Opin. 2008;24(11):3063–72.

Article  CAS  PubMed  Google Scholar 

Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the disease specific programme. BMJ Open. 2016;6(8):e010352.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Higgins V, Piercy J, Roughley A, Milligan G, Leith A, Siddall J, et al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 2016;9:371–80.

Article  PubMed  PubMed Central  Google Scholar 

Pickard AS, Law EH, Jiang R, Pullenayegum E, Shaw JW, Xie F, et al. United States valuation of EQ-5D-5L Health States using an international protocol. Value Health. 2019;22(8):931–41.

Article  PubMed  Google Scholar 

EQ-5D-5L User Guide. Version 3.0. Available from: https://euroqol.org/publications/user-guides.

Petrou S, Rivero-Arias O, Dakin H, Longworth L, Oppe M, Froud R, et al. The MAPS reporting statement for studies mapping onto generic preference-based outcome measures: explanation and elaboration. Pharmacoeconomics. 2015;33(10):993–1011.

Article  PubMed  Google Scholar 

Pike J, Dong Y, Piercy J, Booth N, Holdsworth E, Hunter T. Cross-walk of the assessment of spondyloarthritis international society health index and ankylosing spondylitis quality of life scores in ankylosing spondylitis and non-radiographic axial spondyloarthritis patients. Rheumatol Ther. 2021;8(2):849–62.

Article  PubMed  PubMed Central  Google Scholar 

McClure NS, Sayah FA, Ohinmaa A, Johnson JA. Minimally important difference of the EQ-5D-5L Index Score in adults with type 2 diabetes. Value Health. 2018;21(9):1090–7.

Article  PubMed  Google Scholar 

Harrell F. Regression modeling strategies: With applications to linear models, logistic regression, and survival analysis. New York: Springer International Publishing; 2015.

Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.

Article  PubMed  Google Scholar 

Ahmad E, Lim S, Lamptey R, Webb DR, Davies MJ. Type 2 diabetes. Lancet. 2022;400(10365):1803–20.

Article  PubMed  Google Scholar 

GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the global burden of disease study 2021. Lancet. 2023;402(10397):203–34. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01301-6/fulltext.

Hu G, Ding J, Ryan DH. Trends in obesity prevalence and cardiometabolic risk factor control in US adults with diabetes, 1999–2020. Obesity (Silver Spring). 2023;31(3):841–51.

Article  PubMed  Google Scholar 

Nguyen NT, Nguyen XM, Lane J, Wang P. Relationship between obesity and diabetes in a US adult population: findings from the National Health and Nutrition Examination Survey, 1999–2006. Obes Surg. 2011;21(3):351–5.

Article  PubMed  Google Scholar 

StataCorp. Stata Statistical Software: Release 17. College Station: StataCorp LLC.; 2021.

Google Scholar 

Jiang R, Janssen MFB, Pickard AS. US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples. Qual Life Res. 2021;30(3):803–16.

Article  PubMed  Google Scholar 

Report from the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceuticals: Canada. Int J Technol Assess Health Care. 1995;11(4):796–7.

Google Scholar 

Canada’s Drug and Health Technology Agency. Guidelines for the economic evaluation of health technologies: Canada. 4th ed. Ottawa: CADTH; 2017.

Google Scholar 

Guide to the methods of technology appraisal 2013. Available from: https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781.

Agborsangaya CB, Lahtinen M, Cooke T, Johnson JA. Comparing the EQ-5D 3L and 5L: measurement properties and association with chronic conditions and multimorbidity in the general population. Health Qual Life Outcomes. 2014;12(1):74.

Article  PubMed  PubMed Central  Google Scholar 

Yang F, Wong CKH, Luo N, Piercy J, Moon R, Jackson J. Mapping the kidney disease quality of life 36-item short form survey (KDQOL-36) to the EQ-5D-3L and the EQ-5D-5L in patients undergoing dialysis. Eur J Health Econ. 2019;20(8):1195–206.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kay S, Tolley K, Colayco D, Khalaf K, Anderson P, Globe D. Mapping EQ-5D utility scores from the Incontinence Quality of Life Questionnaire among patients with neurogenic and idiopathic overactive bladder. Value Health. 2013;16(2):394–402.

Article  PubMed  Google Scholar 

Iglay K, Hannachi H, Joseph Howie P, Xu J, Li X, Engel SS, et al. Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. Curr Med Res Opin. 2016;32(7):1243–52.

Article  PubMed  Google Scholar 

Kevin MP, Todd MH, Kevin MC, Sheldon XK, Brian JW, Michael WK, et al. Prevalence and recognition of obesity and its associated comorbidities: cross-sectional analysis of electronic health record data from a large US integrated health system. BMJ Open. 2017;7(11):e017583.

Article  Google Scholar 

Boye KS, Ford JH, Thieu VT, Lage MJ, Terrell KA. The association between obesity and the 5-year prevalence of morbidity and mortality among adults with type 2 diabetes. Diabetes Ther. 2023;14(4):709–21.

Article  PubMed  PubMed Central  Google Scholar 

Younossi ZM, Stepanova M, Anstee QM, Lawitz EJ, Wai-Sun Wong V, Romero-Gomez M, et al. Reduced patient-reported outcome scores associate with level of fibrosis in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2019;17(12):2552-2560.e2510.

Article  PubMed